Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome, 42768 [2012-17679]

Download as PDF 42768 Federal Register / Vol. 77, No. 140 / Friday, July 20, 2012 / Notices Foundation Partnerships in NARA’s ceiling of discretionary advisory committees. NARA has determined that the renewal of the Advisory Committee is in the public interest due to the expertise and valuable advice the Committee members provide on issues affecting the functioning of existing Presidential libraries and library programs and the development of future Presidential libraries. NARA will use the Committee’s recommendations in its implementation of strategies for the efficient operation of the Presidential libraries. SUPPLEMENTARY INFORMATION: NARA’s Committee Management Officer is Mary Ann Hadyka. She can be reached at 301–837–1782. Dated: July 16, 2012. David S. Ferriero, Archivist of the United States. [FR Doc. 2012–17731 Filed 7–19–12; 8:45 am] BILLING CODE 7515–01–P OFFICE OF NATIONAL DRUG CONTROL POLICY Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome AGENCY: Office of National Drug Control for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend the meeting should telephone ONDCP’s Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395– 7454 to arrange building access. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395–7454 or email rsvp@ondcp.eop.gov. Dated: July 16, 2012. Linda V. Priebe, Deputy General Counsel. [FR Doc. 2012–17679 Filed 7–19–12; 8:45 am] BILLING CODE 3180–W1–P Policy. ACTION: Notice. NATIONAL SCIENCE FOUNDATION An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 at the White House Conference Center at 726 Jackson Place, NW., Washington D.C., starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 18:18 Jul 19, 2012 Jkt 226001 Advisory Committee for Mathematical and Physical Sciences; Notice of Meeting In accordance with Federal Advisory Committee Act (Pub. L. 92–463, as amended), the National Science Foundation announces the following meeting: Name: Directorate for Mathematical and Physical Sciences Advisory Committee (MPSAC). #66. Date/Time: August 16, 2012 2:00 p.m.–4:00 p.m. Place: National Science Foundation, 4201 Wilson Boulevard, Arlington, VA 22230, Room 1235. Type of Meeting: Open. Contact Person: Dr. Morris L. Aizenman, Senior Science Associate, Directorate for Mathematical and Physical Sciences, Room 1005, National Science Foundation, 4201 Wilson Boulevard, Arlington, VA 22230. (703) 292–8807. Purpose of Meeting: To provide advice and recommendations concerning NSF science and education activities within the Directorate for Mathematical and Physical Sciences. PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 Agenda: Report of the Portfolio Review subcommittee for the Division of Astronomical Science Report of the NSF Materials 2022 subcommittee for the Division of Materials Research. Summary Minutes: May be obtained from the contact person listed above. Dated: July 17, 2012. Susanne E. Bolton, Committee Management Officer. [FR Doc. 2012–17698 Filed 7–19–12; 8:45 am] BILLING CODE 7555–01–P NUCLEAR REGULATORY COMMISSION [Docket No. 50–423; NRC–2012–0044] Central Vermont Public Service Corporation, Millstone Power Station, Unit 3; Notice of Consideration of Approval of Transfer of Facility Operating License, Conforming Amendment and Opportunity for a Hearing Nuclear Regulatory Commission. ACTION: Notice of request for license transfer and conforming license, opportunity to comment, opportunity to request a hearing. AGENCY: Comments must be filed by August 20, 2012. A request for a hearing must be filed by August 9, 2012. ADDRESSES: Please include Docket ID NRC–2012–0044 in the subject line of your comments. Comments submitted in writing or in electronic form will be posted on the NRC Web site and on the Federal rulemaking Web site https:// www.regulations.gov. Because your comments will not be edited to remove any identifying or contact information, the NRC cautions you against including any information in your submission that you do not want to be publicly disclosed. The NRC requests that any party soliciting or aggregating comments received from other persons for submission to the NRC inform those persons that the NRC will not edit their comments to remove any identifying or contact information, and therefore, they should not include any information in their comments that they do not want publicly disclosed. You may submit comments by any one of the following methods. Federal Rulemaking Web Site: Go to https://www.regulations.gov and search for documents filed under Docket ID NRC–2012–0044. Address questions about NRC dockets to Carol Gallagher 301–492–3668; email Carol.Gallagher@nrc.gov. DATES: E:\FR\FM\20JYN1.SGM 20JYN1

Agencies

[Federal Register Volume 77, Number 140 (Friday, July 20, 2012)]
[Notices]
[Page 42768]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-17679]


=======================================================================
-----------------------------------------------------------------------

OFFICE OF NATIONAL DRUG CONTROL POLICY


Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure 
and Neonatal Abstinence Syndrome

AGENCY: Office of National Drug Control Policy.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: An ONDCP Leadership Meeting on Maternal, Fetal and Infant 
Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring 
together leaders in the field of policy, opioid exposed infants, pain 
treatment during pregnancy, and addiction treatment during and after 
pregnancy. The meeting will be held on Thursday, August 30th 2012 at 
the White House Conference Center at 726 Jackson Place, NW., Washington 
D.C., starting at 9:00 a.m. and concluding at 5:30 p.m. The overall 
objectives of the meeting are to review the state of science and policy 
and discuss the remaining challenges to the field concerning the 
upswing in maternal prescription drug abuse and dependence and 
resulting increases in opioid exposed babies with NAS and possibly 
other consequences. Misuse and abuse of, and dependence upon, 
prescription opioid drugs adversely affect the health of millions of 
Americans and their families.
    The specific conference objectives are: (1) To share research 
findings concerning the NAS epidemic and its costs; (2) to begin a 
national discussion concerning promising and best practices for 
treating opioid exposed babies; (3) to raise awareness about opioid 
misuse and dependence during pregnancy and the need for women with drug 
use disorders to access treatment through family medicine and 
gynecological practitioners, and specialty treatment providers; (4) to 
discuss legal and policy issues related to opioid using pregnant women 
and mothers including barriers to accessing treatment; (5) to promote 
awareness among regulatory agencies and insurers concerning the risks 
and benefits of opioids to developing fetuses and the likelihood of 
neonatal abstinence syndrome resulting from long term opioid use during 
pregnancy; and (6) to raise awareness about risk prevention 
opportunities among practitioners and regulators. Members of the public 
who wish to attend the meeting should telephone ONDCP's Maternal, 
Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome 
telephone line at (202) 395-7454 to arrange building access.
    To Attend or For Further Information Contact: Cecelia Spitznas, 
Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.

    Dated: July 16, 2012.
Linda V. Priebe,
Deputy General Counsel.
[FR Doc. 2012-17679 Filed 7-19-12; 8:45 am]
BILLING CODE 3180-W1-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.